Business
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for ...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Feb. 11, 2020\n\n\n\nPrimary Endpoint Achieved with High Statistical Significance\n\n \n \n\n \nLAVAL, QC, Feb. 11, 2020 /CNW/ – Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (\"Crescita\" or the \"Company\"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced positive topline results from two pivotal Phase 3 clinical trials for an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company's patented Multiplexed Molecular Penetration Enhancer (\"MMPE™\") technology. The studies were conducted by the Company's partners including Ferndale Laboratories, Inc. (\"Ferndale\"). \nThe two Phase 3 multi-centre, randomized, vehicle-controlled, double-blind, parallel group trials were conducted in the United States using the same study design. Both studies met the primary endpoint demonstrating that a statistically significant greater number of patients achieved the Investigator's Global Assessment (\"IGA's\") treatment success (p< 0.001) at the end of study. The IGA score is a static evaluation by the investigator of the overall assessment of the patient's disease status within the designated treatment area. These results are based on the Intent To Treat (\"ITT\") population and study results in the Per Protocol (\"PP\") population were also highly significant as were key secondary endpoints for both studies.\nSerge Verreault, Crescita's President and CEO commented: \"These impressive study results support our continued belief that this product can have a clinically meaningful benefit for the treatment of patients suffering from moderate to sev...